| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-10-09 | novel corrector series including potentiator GLPG1837 and a prototype corrector C18 | cystic fibrosis |
Galapagos (Belgium) | Rare diseases - Genetic diseases | |
| 2014-10-09 | NuQ® assays | colorectal cancer |
VolitionRx (Singapore) Hvidovre Hospital (Denmark) | Cancer - Oncology | |
| 2014-10-08 | fidaxomicin (Dificid®) | Clostridium difficile-associated diarrhea (CDAD) |
1 | Cubist Pharmaceuticals (USA - MA) | Infectious diseases |
| 2014-10-08 | CEP-33237 (Hydrocodone Bitartrate) Extended-Release Tablets | chronic pain |
3 | Teva Pharmaceutical Industries (Israel) | CNS diseases |
| 2014-10-08 | ABP 501 (biosimilar version of Humira® (adalimumab)) | moderate-to-severe plaque psoriasis | 3 | Amgen (USA - CA) | Autoimmune diseases - Dermatological diseases |
| 2014-10-08 | eravacycline (7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline) | preclinical | Tetraphase Pharmaceuticals (USA - MA) | Infectious diseases | |
| 2014-10-07 | TPM®/Tretinoin topical gel formulation | acne vulgaris |
2 | Phosphagenics (Australia) | Dermatological diseases |
| 2014-10-07 | APD421 (intravenous formulation of a currently marketed dopamine D2 antagonist for the new use of prevention and treatment of nausea & vomiting) | prevention of post-operative nausea & vomiting (PONV) |
3 | Acacia Pharma (UK) | Gastrointestinal diseases - Digestive diseases |
| 2014-10-06 | undisclosed new RNAi based drug | cirrhosis |
1b | Nitto Denko (Japan) | Hepatic diseases - Liver diseases |
| 2014-10-06 | Collategene® (beperminogene perplasmid) | critical limb ischemia |
3 | Anges MG (Japan) | Cardiovascular diseases |
| 2014-10-06 | metadoxine extended release (MDX) | Attention Deficit Hyperactivity Disorder (ADHD) | 3 | Alcobra (Israel) | Mental diseases - CNS diseases |
| 2014-10-06 | eravacycline (7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline) | complicated urinary tract infections (cUTI) |
3 | Tetraphase Pharmaceuticals (USA - MA) | Infectious diseases |
| 2014-10-06 | IBI-10090 | ocular inflammation following cataract surgery |
3 | Icon Bioscience (USA - CA) | Ophtalmological diseases - Inflammatory diseases |
| 2014-10-06 | FDX104 (topical formulation of doxycycline) | prevention of rash in cancer patients taking epidermal growth factor receptor inhibitors (EGFRI) |
2 | Foamix Pharmaceuticals (Israel - USA - NJ) | Cancer - Oncology - Dermatological diseases |
| 2014-10-02 | NAITgam | prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) |
1-2 | Prophylix Pharma (Norway) | Hematological diseases - Autoimmune diseases |
| 2014-10-01 | evolocumab | heterozygous familial hypercholesterolemia | 3 | Amgen (USA - CA) | Cardiovascular diseases - Genetic diseases - Rare diseases |
| 2014-10-01 | GNS396 | acute myeloid leukemia |
preclinical | Genoscience Pharma (France) | Cancer - Oncology |
| 2014-10-01 | GNS561 | hepatocellular carcinoma |
preclinical | Genoscience Pharma (France) | Cancer - Oncology |
| 2014-10-01 | evolocumab | homozygous familial hypercholesterolemia | 3 | Amgen (USA - CA) | Rare diseases - Cardiovascular diseases |
| 2014-10-01 | lirilumab (BMS-986015) and elotuzumab (BMS-901608) | multiple myeloma | 1 | BMS (USA - NY) Innate Pharma (France) | Cancer - Oncology |
